arznei-telegramm Logo a-t Kurzlogo
    ❮ a-t 9/2018 a-t ❯
    This is a translation of the table of contents. One article of each issue is translated and freely available.
    table of contents
    SPOT ON

    From valsartan to Lunapharm … what are the consequences?

    THERAPY FROM A CRITICAL VIEWPOINT

    New indication – rivaroxaban (XARELTO) for stable coronary heart disease and peripheral arterial disease

    a-t READERS QUESTIONS AND COMMENTS

    Aluminium in vaccines

    IN BRIEF

    Antidepressant agomelatine (VALDOXAN) – risk mitigation measures are not followed

    ALZHEIMERs drugs no longer reimbursed in France
    free

    Supply shortage – expiry dates of epinephrine auto-injectors extended

    Diabetes – omega-3 fatty acids for cardiovascular prevention?

    Vacuum wound treatment – data under lock and key

    SIDE EFFECTS

    Diabetes mellitus: FOURNIER gangrene with SGLT-2 inhibitors

    Daclizumab: encephalitis even months after discontinuation

    Restrictions of use of IBEROGAST – 10 years too late

    e a-t ON THE INTERNET

    “Flu” vaccines 2018/19

    arznei-telegramm

    Independent drug information – in English

    Concise, critical evaluations of drugs and medical devices for evidence-based therapy and patient advice on benefits and risks – independent, ad-free and funded exclusively by subscriptions.

    Browse free articles